Completed PHASE3 INTERVENTIONAL 2-arm NCT00106340

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Sponsor: Novartis Pharmaceuticals

Interventions Glimepiride matching placebo Metformin Vildagliptin matching placebo glimepiride vildagliptin

Updated 8 times since 2017 Last updated: Dec 11, 2020 Started: Mar 31, 2005 Primary completion: May 31, 2008 Completion: May 20, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00106340, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Hanover, United States
• Nuremberg, Germany